This book highlights recent developments of organic and inorganic nanomedicine that play a major role in anti-angiogenic cancer therapy. In addition, the authors present examples of nanomedicine based anti-angiogenic agents and their applications in cancer therapy. Angiogenesis is a pathophysiological phenomenon that modulates cell proliferation and cell migration and plays important roles in cancer. Anti-angiogenic nanotherapies have gained immense attention in recent times as alternative cost-effective therapies that opened a new dimension in cancer theranostics. Further the challenges of the anti-angiogenic nanotherapies and possible future perspective are detailed.
Chapter 1 - Introduction.
Chapter 2 - Current Anti-angiogenic Therapies
and their Limitations.
Chapter 3 - Nanomedicine.
Chapter 4 - Organic
Nanoparticles in Anti-angiogenic Cancer Therapy.
Chapter 5 - Inorganic
Nanoparticles in Anti-angiogenic Cancer Therapy.
Chapter 6 - Potential
Challenges in Anti-angiogenic Nanotherapies.
Chapter 7 - Conclusion.
Sudip Mukherjee, Ph.D., is a Research Scientist at Rice University. His research interests include the development of advanced biomaterials for cell therapy, drug/gene delivery in diabetes, cancer theranostics, angiogenesis, and immunomodulatory applications. Dr. Mukherjee serves as an Associate Editor for various journals including BMC Cancer and Frontiers in Chemistry and is also a reviewer for several international journals, such as Chem Comm, Journal of Materials Chemistry A, Journal of Materials Chemistry B, ACS Nano, Biomaterials, RSC Advances, IOP Nanotechnology, and Biofabrication.
Vijay Sagar Madamsetty, Ph.D., is a senior postdoctoral fellow at the Mayo Clinic Florida in the Department of Biochemistry and Molecular Biology. He is currently developing multiple drugs/genes encapsulating targeted nanoformulations and their preclinical evaluation in several disease animal models. Dr. Madamsettys research interests involve understanding key signaling pathways andhow alterations in gene expression contribute to human diseases, leading to developing effective targeted nanomedicine. He is also an active reviewer and editorial board member of several international journals.
Lisainfo e-raamatute kohta